{"disease":{"id":"relapsed-aml","name":"relapsed aml"},"drugs":{"marketed":[{"drug_id":"gemtuzumab-ozogamicin","indication_name":"Relapsed or refractory CD33-positive AML","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"gemtuzumab-ozogamicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"100","mechanism":"Mylotarg works by binding to CD33 on cancer cells and releasing a toxic compound that kills the cells."},{"drug_id":"gemtuzumab","indication_name":"relapsed or refractory CD33-positive AML","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"GEMTUZUMAB","company_name":"Wyeth Pharms Inc","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"100","mechanism":"Mylotarg targets and binds to CD33-positive cancer cells, delivering a cytotoxic agent to destroy them."},{"drug_id":"chembl-chembl1201506","indication_name":"Relapsed or refractory CD33-positive AML","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GEMTUZUMAB OZOGAMICIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"revumenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revuforj","generic_name":"REVUMENIB","company_name":"Syndax","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Revuforj works by inhibiting an enzyme that is involved in the growth and survival of cancer cells."},{"drug_id":"ziftomenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Komzifti","generic_name":"ZIFTOMENIB","company_name":"Kura","drug_phase":"marketed","molecular_target":"","drug_class":"Menin Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells."},{"drug_id":"ziftomenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Komzifti","generic_name":"ZIFTOMENIB","company_name":"Kura","drug_phase":"marketed","molecular_target":"","drug_class":"Menin Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07084584","title":"An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":184,"lead_sponsor_name":"Galecto Biotech AB","has_results":false},{"nct_id":"NCT05193448","title":"A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE","phase":"","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT05054543","title":"Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":140,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT04824794","title":"GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":130,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT02520427","title":"A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":95,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03218683","title":"Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04113616","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03541369","title":"Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":64,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06869265","title":"Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06532058","title":"Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":53,"lead_sponsor_name":"Changzhou Qianhong Bio-pharma Co., Ltd.","has_results":false},{"nct_id":"NCT07026942","title":"Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Nationwide Children's Hospital","has_results":false},{"nct_id":"NCT03516760","title":"Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"AvenCell Europe GmbH","has_results":false},{"nct_id":"NCT06613217","title":"Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Pacylex Pharmaceuticals","has_results":false},{"nct_id":"NCT04139434","title":"Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Newave Pharmaceutical Inc","has_results":false},{"nct_id":"NCT07500753","title":"A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05305859","title":"Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT04033627","title":"TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Shanghai Children's Medical Center","has_results":false},{"nct_id":"NCT04722952","title":"PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04310592","title":"Natural Killer Cell (CYNK-001) Infusions in Adults with AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Celularity Incorporated","has_results":false},{"nct_id":"NCT07156435","title":"Vyxeos® With Clofarabine for Pediatric AML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Princess Maxima Center for Pediatric Oncology","has_results":false},{"nct_id":"NCT05226468","title":"An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"New Epsilon Innovation Limited","has_results":false},{"nct_id":"NCT07233018","title":"A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"MEI HENG","has_results":false},{"nct_id":"NCT06307054","title":"CLL-1 CAR-NK Cells for Relapsed/Refractory AML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT07355335","title":"Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06709131","title":"A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":24,"lead_sponsor_name":"He Huang","has_results":false},{"nct_id":"NCT03787498","title":"A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Opna Bio LLC","has_results":false},{"nct_id":"NCT05029141","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05805072","title":"Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03091933","title":"Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Ciusss de L'Est de l'Île de Montréal","has_results":false},{"nct_id":"NCT03631576","title":"CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT05241093","title":"A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Tarapeutics Science Inc.","has_results":false},{"nct_id":"NCT06786299","title":"Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT07441980","title":"A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05241106","title":"A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Tarapeutics Science Inc.","has_results":false},{"nct_id":"NCT03848754","title":"Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT06563804","title":"A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Servier Bio-Innovation LLC","has_results":false},{"nct_id":"NCT04839341","title":"Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT06649227","title":"Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":5,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT03473457","title":"CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia","phase":"NA","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT04562792","title":"Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Children's Mercy Hospital Kansas City","has_results":true},{"nct_id":"NCT05345938","title":"A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT06586099","title":"Tislelizumab with Azacitidine in the Treatment of R/R AML","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03560908","title":"Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05622591","title":"ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Elucida Oncology","has_results":false},{"nct_id":"NCT03245424","title":"Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":false}],"total":45},"guidelines":[],"source":"Drug Landscape verified database"}